Tao J, Zhang Y, Wang T
Iran J Public Health. 2021; 49(11):2044-2053.
PMID: 33708725
PMC: 7917512.
DOI: 10.18502/ijph.v49i11.4719.
Yang L, Dong X, Xing X, Cui X, Li L, Zhang L
World J Gastrointest Oncol. 2020; 12(11):1346-1363.
PMID: 33250966
PMC: 7667450.
DOI: 10.4251/wjgo.v12.i11.1346.
Zhao J, Lei T, Zhang T, Chen X, Dong J, Guan Y
Ann Transl Med. 2020; 8(18):1160.
PMID: 33241009
PMC: 7576073.
DOI: 10.21037/atm-20-4366.
Jin X, Zheng X, Chen D, Jin J, Zhu G, Deng X
Eur Radiol. 2019; 29(11):6080-6088.
PMID: 31028447
DOI: 10.1007/s00330-019-06193-w.
Anestis A, Zoi I, Karamouzis M
Ann Transl Med. 2018; 6(12):247.
PMID: 30069449
PMC: 6046293.
DOI: 10.21037/atm.2018.04.42.
Radiotherapy for esophageal carcinoma: dose, response and survival.
Luo Y, Mao Q, Wang X, Yu J, Li M
Cancer Manag Res. 2018; 10:13-21.
PMID: 29343986
PMC: 5749557.
DOI: 10.2147/CMAR.S144687.
Meta-Analysis of the Relationship between NM23 Expression to Gastric Cancer Risk and Clinical Features.
Fang M, Tao Y, Liu Z, Huang H, Lao M, Huang L
Biomed Res Int. 2017; 2017:8047183.
PMID: 28401162
PMC: 5376405.
DOI: 10.1155/2017/8047183.
The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients.
Zhang M, Dong Y, Liu H, Zhao S, Xuan Q, Wang Y
Sci Rep. 2016; 6:37933.
PMID: 27892511
PMC: 5124943.
DOI: 10.1038/srep37933.
FOXO3a promotes gastric cancer cell migration and invasion through the induction of cathepsin L.
Yu S, Yu Y, Zhang W, Yuan W, Zhao N, Li Q
Oncotarget. 2016; 7(23):34773-84.
PMID: 27127880
PMC: 5085188.
DOI: 10.18632/oncotarget.8977.
Involved-field radiotherapy for esophageal squamous cell carcinoma: theory and practice.
Li M, Zhang X, Zhao F, Luo Y, Kong L, Yu J
Radiat Oncol. 2016; 11:18.
PMID: 26846932
PMC: 4743321.
DOI: 10.1186/s13014-016-0589-7.
Gastric Cancer: New Drugs - New Strategies.
Schulte N, Ebert M, Hartel N
Gastrointest Tumors. 2015; 1(4):180-94.
PMID: 26674336
PMC: 4668795.
DOI: 10.1159/000380786.
Activation of FOXO3a suggests good prognosis of patients with radically resected gastric cancer.
Yu S, Yu Y, Sun Y, Wang X, Luo R, Zhao N
Int J Clin Exp Pathol. 2015; 8(3):2963-70.
PMID: 26045805
PMC: 4440114.
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.
Fontes Jardim D, Gagliato D, Falchook G, Janku F, Zinner R, Wheler J
Oncotarget. 2014; 5(7):1837-45.
PMID: 24742823
PMC: 4039117.
DOI: 10.18632/oncotarget.1828.
C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.
Yu S, Yu Y, Zhao N, Cui J, Li W, Liu T
PLoS One. 2013; 8(11):e79137.
PMID: 24223894
PMC: 3817069.
DOI: 10.1371/journal.pone.0079137.
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
Lennerz J, Kwak E, Ackerman A, Michael M, Fox S, Bergethon K
J Clin Oncol. 2011; 29(36):4803-10.
PMID: 22042947
PMC: 3255989.
DOI: 10.1200/JCO.2011.35.4928.
